dehydrated alcohol
DEHYDRATED ALCOHOL (dehydrated alcohol) is intra-arterial catheter into a target septal vessel, which causes the hypertrophied septum to thin. First approved in 2025.
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
Dehydrated alcohol is an intravenous solution administered via intra-arterial catheter into target septal vessels to treat hypertrophic cardiomyopathy. The mechanism involves alcohol-induced septal ablation, causing the hypertrophied septum to thin and improve cardiac hemodynamics. This is a specialized interventional cardiology product with a narrow but critical patient population.
Early-stage launch with competitive pressure at 30%, indicating a moderately crowded niche market requiring focused commercial execution and specialist engagement.
intra-arterial catheter into a target septal vessel, which causes the hypertrophied septum to thin.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
This newly launched product offers career opportunities in specialized hospital-based cardiology roles with emphasis on physician relationship-building and interventional expertise. The niche market and procedural nature create demand for highly specialized sales and medical affairs talent rather than broad primary care teams.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo